An open-label clinical trial of oral ketamine, an NMDA (N-methyl-D-aspartate) receptor antagonist, with weekly dosing over six weeks, in 25-50 patients who are experiencing chronic suicidal ideation.

Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast0 个研究点目标入组 40 人开始时间: 2018年8月23日最近更新: 2021年2月1日

试验速览

暂无简介。

•Patients with chronic suicidal thoughts as the primary presenting complaint, determined by a score of greater than or equal to 6 for the Scale for Suicide Ideation (BSS)
•Persons (male/female/other) aged over 18 years
•Participant to receive physical examination from Principal Investigator within 14 days prior to commencement of ketamine treatment to eliminate possibility of conditions outlined in
•exclusion criteria
•Participants must be able to understand the PIF and provide written informed consent on the Participant Consent Form (PCF)

•Persons under 18 years of age
•Psychosis
•Mania/hypomania
•Acute suicidality requiring urgent psychiatric intervention
•Uncontrolled/severe symptomatic cardiovascular disease states including: recent myocardial infarction (within prior 6 months); history of stroke; and hypertension (resting blood pressure >150/100)
•History of intracranial mass, intracranial haemorrhage/stroke, cerebral trauma/traumatic brain injury or increased intracranial pressure (as assessed by referring general practitioner)
•Liver function test (LFT) results that exceed the upper level of normal range by 3 times
•Previous reaction to ketamine (as reported by referring general practitioner and participant)
•Pregnant women
•Breastfeeding women

发起方

Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast